Analysts await Chiasma, Inc. (NASDAQ:CHMA) to report earnings on Mar, 14 for the fiscal quarter ending Dec 2015.

They expect $-0.53 EPS, down 100% or $0.53 from last year’s $n/a per share.

At the moment 4 analysts are watching Chiasma, Inc. (NASDAQ:CHMA), 2 rate it “Buy”, 2 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Mar-16, 1 analyst has a mean sales target of 0.00 million. For the quarter ending Jun-16, 1 analyst has a mean sales target of 0.00 million whilst for the year ending Dec-16, 4 analysts have a mean target of 17.79 million.

In terms of earnings per share, 3 analysts have a -0.52 EPS mean target for the quarter ending Mar-16, for the quarter ending Jun-16, 3 analysts have a -0.58 EPS mean target and for the quarter ending Jun-16 there are 4 estimates of -1.80 EPS.

The biggest institutional shareholders in Chiasma, Inc. include Mpm Asset Management, LLC which owns 6 million shares in the company valued at $111.19 million. MPM BioVentures V LLC is the second biggest holder with 6 million shares currently valued at 111.19 million whilst Fidelity Management and Research Company has 3 million shares valued at 79.85 million.

Total shares held by institutions as of the most recent company filings are 15,576,013 with a reported 43,079 bought and 3,079 sold. These holdings make up 76.96% of the company’s outstanding shares.

The stock increased 4.20% or $0.42 during the last trading session, hitting $15.46. Chiasma, Inc. (NASDAQ:CHMA) has fallen 83.31% over the past 6 months and is downtrending.